DENALI THERAPEUTICS INC. - COMMON STOCK

Denali Therapeutics Announces Initiation of Phase 2 Study by Partner Sanofi of RIPK1-Inhibitor DNL758 (SAR443122) in Cutaneous Lupus Erythematosus (CLE) Patients

28 Jun 2021 05:00:00 By Nasdaq GlobeNewswire

Denali Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights

03 May 2021 05:30:00 By Nasdaq GlobeNewswire

Denali Therapeutics Presents Positive Results from Phase 1 and Phase 1b Studies of Its LRRK2 Inhibitor, BIIB122/DNL151, Supporting Late-Stage Development Plans in Parkinson’s Disease

01 May 2021 06:00:00 By Nasdaq GlobeNewswire

Denali Therapeutics Announces Fast Track Designation Granted by the U.S. FDA to ETV:IDS (DNL310) for the Treatment of Patients with Hunter Syndrome (MPS II)

11 Mar 2021 05:30:00 By Nasdaq GlobeNewswire

Denali Therapeutics Reports Full Year 2020 Financial Results and Business Highlights

25 Feb 2021 13:01:01 By Nasdaq GlobeNewswire

Denali Therapeutics Reports Positive Three-Month Data from Phase 1/2 Study with ETV:IDS (DNL310) in Patients with Hunter Syndrome (MPS II)

12 Feb 2021 04:30:00 By Nasdaq GlobeNewswire

Denali Therapeutics to Present New Data on ETV:IDS (DNL310) for the Potential Treatment of Hunter Syndrome at WORLDSymposium™

05 Feb 2021 06:00:00 By Nasdaq GlobeNewswire

Denali Therapeutics Announces Appointment of Nancy Thornberry to Board of Directors

11 Jan 2021 05:30:00 By Nasdaq GlobeNewswire

Denali Therapeutics Announces Significant Program Progress and Expected Key Milestones in 2021 for Its Broad Therapeutic Portfolio in Neurodegeneration

08 Jan 2021 05:30:00 By Nasdaq GlobeNewswire